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1. Introduction  
Multiple sclerosis (MS) is a common cause of chronic neurological disability in young 
adults. Magnetic Resonance Imaging (MRI) readily identifies multifocal white matter 
lesions(WML) that represent areas of demyelination and is thus useful in supporting the 
diagnosis of MS, even after a single clinical episode(McDonald et al., 2001). MRI is also 
widely used to monitor disease progression in natural history and in therapeutic trial 
studies. However, conventional MRI does not detect the subtle histopathological changes 
that are described in the normal-appearing white matter (NAWM) in patients with 
MS(Allen & McKeown, 1979; Bitsch et al., 1999). MRS has been used in the evaluation of MS 
to help further define the nature of the lesions revealed by T2-weighted MRI(Arnold, 
Matthews, Francis, O'Connor, & Antel, 1992; Arnold et al., 1994; Bitsch et al., 1999; Davie 
et al., 1997; De Stefano et al., 1995; Fu et al., 1998; Gonen et al., 2000; Matthews et al., 1996; 
Narayana, Doyle, Lai, & Wolinsky, 1998; Pan et al., 1996; Rooney et al., 1997; Sarchielli et 
al., 1999; Tourbah et al., 1999; van Walderveen, Barkhof et al., 1999). The measurement of 
N-acetly aspartic acid (NAA) is thought to be a marker of axonal loss, damage or 
dysfunction. Many studies (Arnold et al., 1992; Arnold et al., 1994; Davie et al., 1997; De 
Stefano et al., 1995; Husted et al., 1994; Narayana et al., 1998,( Allen & McKeown, 1979; De 
Stefano et al., 1995; Fu et al., 1998; Husted et al., 1994; Narayana et al., 1998) have shown a 
reduction in the absolute concentration of NAA or the NAA/Cr ratio in MS lesions. 
However, pathological(Allen & McKeown, 1979) and quantitative MRSI 
studies(Armspach, Gounot, Rumbach, & Chambron, 1991; Filippi et al., 1995; Gasperini et 
al., 1996; Loevner et al., 1995) have shown that in patients with clinically definite MS, 
abnormalities also occur in the NAWM(Arnold et al., 1992; Davie et al., 1997; Davie et al., 
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1994; Fu et al., 1998; Husted et al., 1994; Narayana et al., 1998). Although the principal 
finding of MRS studies in patients with MS was a decrease in the NAA peak area, 
opposite results were obtained for other metabolites(Davie et al., 1994; Davies, 
Newcombe, Williams, McDonald, & Clark, 1995; De Stefano et al., 1995; Husted et al., 
1994; Larsson et al., 1991). Despite the difficulties in interpreting data obtained in vivo, 
MRS provides direct information about metabolic variations and the damage to or 
integrity of myelin and axons, which are not revealed by traditional MRI(Arnold et al., 
1994; Ferguson, Matyszak, Esiri, & Perry, 1997; Fernando et al., 2004). 
In patients with relapsing remitting multiple sclerosis (RRMS), interferons reduce the attack 
frequency of the disease, the mean attack duration, the annual lesion burden, and the 
frequency of gadolinium (Gd) enhancement on MRI. However the mechanism of action of 
interferons in patients with MS and the effect of interferons on axonal injury remain 
undefined. We questioned whether treatment with interferon beta-1a (INF-1a) would 
enable the recovery of injured axons. To determine this, we used MRSI to examine changes 
in the metabolic peaks of neuronal markers NAA, Cho(Choline), and Cr(Creatine) after 
treatment with INF-1a(Rebif 44 g) in a small group of patients with RRMS. An untreated 
group was studied for comparison, and healthy volunteers were used as controls.  
2. Materials and methods 
2.1 Patients and methods 
We studied 10 patients (7 women 3 men) with clinically definite RRMS (median age, 39 
years; age range 22-50 years). The median expanded status scale score (EDSS) was 2.1 (range 
1.0-3.0), and the median duration of disease was 4.7 years (range, 1-20 years). In the 2 years 
before their participation in the study, all patients had had at least one relapse. None of the 
patients had undergone immunosuppressant therapy ever before, or corticosteroid 
treatment within 2 months before the initiation of the study. Five patients elected not to be  
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Fig. 1. a-f: Axial fluid-attenuated, inversion recovery (FLAIR) MR image of a 50-year-old 
woman receiving INF-1a treatment shows a voxel placed over a WM lesion in the right 
centrum semiovale (1a). The multivoxel CSI MRI spectrum of this lesion is obtained during 
study months zero, 1, 3, 6, and 12 (b-f). The results of proton MRSI show that there is a 
statistically significant increment in absolute NAA and Cho values.  
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treated. Five other patients received INF-1a treatment. All patients were evaluated at the  
beginning of the study and during the first, third, sixth, and twelfth month. During their 
follow-up evaluations, neurological examinations that included EDSS assessment were 
performed in addition to MR studies with gadopentetate dimegluminelinium (Gd) 0,1 
mmol/kg intravenously, and MRSI (Figure 1a-f). A relapse was defined as the appearance 
of new neurological symptoms or worsening of prior neurological symptoms of 48 hours’ 
duration in addition to objective evidence of a change in neurological status of a patient who 
has been clinically stable for the 4 prior weeks. All patients suspected of having an attack 
were examined within 7 days of the onset of symptoms and were treated with intravenous 
methyprednisolone (IVMP) at a dose of 1 g/day for 5 days. At the beginning of the study, 
MRI and MRSI studies were also performed on 6 healthy, age-matched and sex-matched 
control subjects (4 women, 2 men; median age, 33.6 years, age range, 27-48 years) who had 
neither systemic nor neurologic disease. The local ethics committee approved the study.  
2.1.1 MRI studies 
All MRI and MRSI studies were performed with a 1.5 Tesla MR unit (Siemens Magnetom 
Symphony, Erlangen, Germany) with a standard quadrature head coil. To detect focal WM 
lesions, we used conventional MRI, including axial T1 weighted (TR 586 ms, TE 15 ms, 5 
mm slice thickness), fluid-attenuated, inversion recovery (FLAIR) (TR 9000 ms, TE 98 ms, 5 
mm slice thickness), axial and sagittal proton density (TR 2200 ms, TE 30 ms, 5 mm slice 
thickness), T2-weighted spin echo sequences (TR 2200 ms, TE 80 ms, 5 mm slice thickness) 
and post-gadolinium axial and sagittal T1 weighted (TR 779 ms, TE 15 ms, 5 mm slice 
thickness) spin echo sequences. MRI images were acquired with a matrix size of 145x256 
mm and FOVof 230x230 mm. During the same session, water-suppressed proton MRSI was 
performed by means of multivoxel chemical shift imaging (TR/TE: 1500/135, voxel volume 
1 cm3). Metabolite peaks of NAA, Cho, and Cr were assessed in both WML -without Gd 
enhancement- and in NAWM.  
2.1.2 Statistics 
SPSS 11 for Windows was used for statistical analysis. The Kruskal-Wallis Test was used to 
compare the basal NAWM metabolite peaks among treated, untreated and healthy control 
subjects. The Mann-Whitney U test was used to compare the basal WML metabolite peaks in 
treated and untreated patients. Then, multivariate analysis of variance (MANOVA) was 
used to compare the NAWM and WML metabolite peaks in treated and untreated patients 
throughout the study period. The Wilcoxon signed rank test was used to compare changes 
in the NAWM and WML metabolite peaks during study months zero, 1, 3, 6, and 12. Results 
with p< .05 were considered as significant.  
3. Results 
3.1 Treatment effect as assessed by relapse rate, and new T2 lesions with and without 
GD enhancement 
Five patients (3 women and 2 men) elected not to be treated. Four of those 5 patients 
experienced no attacks during the 12 months of the study. However, the results of MRI 
examination revealed new Gd-enhancing lesions without a trace of an accompanying 
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clinical MS attack at the initiation of the study in 3 patients during the sixth month of the 
study. The results of serial MR examinations of another patient revealed new T2 lesions 
without Gd-enhancement that were present without evidence of a clinical MS attack from 
the initiation of the study until the twelfth study month. However, during the twelfth 
month, that patient experienced a clinical MS attack (moderate paresis [4/5] of the left leg), 
and a new Gd-enhancing lesion was identified. And only that patient received pulse steroid 
therapy once daily for 5 days.  
Five other patients received INF-1a treatment (subcutaneous INF-1a 44 µg –Rebif-3 times 
per week). Among the subjects who received INF, two patients had Gd-enhancing new T2 
lesions on almost every MRI examination, another patient had a Gd-enhancing lesion only 
on the last MRI examination of the study, and the remaning patients exhibited no new 
lesions. None of those patients experienced a clinical MS attack accompanying the MRI 
activities. There was no significant change in the EDSS scores of the patients in either group 
throughout the study.  
3.2 MRSI results 
There was no statistically significant difference between the basal metabolite levels in the 
NAWM of patients with MS and the healthy control subjects (P> .005) (Table 1). There was 
also no statistically significant difference between the basal metabolite peaks in the WML 
between the untreated and treated MS patients (Table 2).  
NAWM metabolic peaks  NAA Basal CHO Basal CR Basal 
Untreated Mean 6,5±4,6 4,3±1,9 3,9±1,8 
 Median 4,8950 3,4650 3,1650 
Treated Mean 7,1±2,3 4,5±1,4 4,3±1,3 
 Median 7,8100 4,7550 4,5200 
Control Mean 6,8±0,4 4,1±0,7 4,0±0,2 
 Median 6,9250 4,2900 3,9800 
WML metabolic peaks  NAA Basal CHO Basal CR Basal 
Untreated Mean 6,03,7 4,41,9 3,81,8 
 Median 4,8900 4,6700 3,1900 
Treated Mean 6,82,5 4,81,6 3,91,2 
 Median 5,4800 5,0950 3,7900 
NAA: N-acetyl aspartate, Cho: Choline, Cr: Creatine  
Table 1. Basal normal-appearing white matter and white matter metabolite levels in treated 
and untreated patients and controls 
We analyzed whether any difference emerged in the NAWM metabolite peaks between the 
treated and untreated patients throughout the study period and found that a significant 
difference existed in NAWM NAA peaks (P = .003); Cho peaks (P = .001); and Cr peaks (P = 
.006) beginning from the first month of the study. When we evaluated the groups separately to 
assess when that difference emerged between the basal and the following months’ NAA, Cho 
and Cr peaks we noted that in the treatment group, the NAA peaks began to increase during 
the sixth month (P = .000); Cho peaks increased during the sixth and twelfth months (P = .000); 
and an increment in the Cr peak was found in the third (P< .04), sixth (P = .001), and twelfth 
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study months (P = .00). However, in the untreated group, none of the NAA, Cho or Cr peaks 
(in NAWM) varied significantly during the entire study period (P> .05) (Graphic 1). 
 
Graphic 1. 
 
 
Graphic 2. 
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We found a significant difference between the changes in WML NAA (P= .001), Cho (P = 
.025); and Cr (P = .031) peaks of untreated and treated patients, beginning from the first 
month. When we evaluated the groups separately to determine when the difference 
emerged between the basal WML NAA peaks and the following months’ NAA peaks, we 
noted that the NAA peaks started to increase during the sixth month in the treatment group 
(P = .001); the Cho peak started to increase during the first month (P = .03); and the Cr peak 
began to increase during the third month in the treatment group (P = .04). However, NAA, 
Cho or Cr peaks did not vary significantly in WML over the entire period of study in the 
untreated group (P > .05) (Graphic 2). 
4. Discussion 
In this study, variations in cerebral metabolites were assessed during treatment with INF-
1a in a small group of patients with RRMS, and the results were compared with those in 
untreated patients matched for age and disability. We used the absolute quantification of the 
metabolites. The use of ratios is potentially less sensitive to the effects of disease in MS than 
is the use of absolute values; measurement error may be increased when two measures 
rather than one are required(Fernando et al., 2004). The use of the ratio to Cr also requires 
the assumption that Cr is normal in the patients’ NAWM. However, there have been reports 
of abnormalities of Cr levels in demyelinating lesions and in the NAWM in patients with 
MS(Brex et al., 1999; Pan et al., 1996; Rooney et al., 1997; Suhy et al., 2000; van Walderveen, 
Truyen et al., 1999). Pan and colleagues found an isolated increase in Cr without a change in 
the level of Cho or NAA in the NAWM(Pan et al., 1996)of patients with MS. An increase in 
Cr was also found in a clinically isolated syndrome (CIS) group(Fernando et al., 2004). In 
that study, an increase in Cr was found in a subgroup of subjects with abnormal T2-
weighted MRI results and in those with MS defined according to the McDonald 
criteria(Fernando et al., 2004). Those studies suggest that Cr may not be a reliable internal 
standard for use in the investigation of the effects of demylinating disease upon metabolite 
concentrations.  
We have found no significant difference between the basal metabolite peak areas of NAA, 
Cho and Cr in the NAWM of patients with MS and that of healthy controls (P >.005). This 
was attributed to the patients’ having been on relatively early stages of the disease 
(primarily 2-5 years after diagnosis) and their low EDSS levels. Those factors indicate that 
widespread axonal damage either had not occurred or was not detectactable at this stage 
and that the reduced NAA found in established MS is acquired later in the disease course. In 
a study, when 15 clinically isolated syndrome patients with T2 abnormalities were 
considered separately, their NAWM NAA concentrations were not found to be significantly 
different from those in controls(Brex et al., 1999). In our study, there was no significant 
difference between NAWM metabolite peaks of the treated and untreated groups in the 
results of the initial MRSI (P> .005) showing that the 2 patient groups were homogenous. 
We found that in the treatment group, NAWM NAA and Cho peaks began to increase 
during the sixth month, and that Cr peaks began to increase during the third month. No 
change was observed in the untreated group. When we evaluated WML metabolite changes, 
we found that in the treatment group, NAA and Cr peaks began to increase during the third 
month and Cho peaks began to increase during the first month. No changes in the 
metabolite peak areas of WML were observed in the untreated group.  
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There are a number of possible explanations for the increase in NAA that occurred between 
the sixth and twelfth months of treatment. Chronic low-grade encephalitis is probably 
present in patients with MS. There is pathological evidence of an increase in inflammatory 
cells in the NAWM of such patients(Allen & McKeown, 1979). The results of studies using 
Gd-enhanced MRI suggest that the blood-brain barrier is diffusely impaired in patients with 
MS. This chronic, low-level inflammation could result in widespread, partially reversible 
axonal damage and loss, and INF could induce its reversal.  
A number of tissue injury mediating factors have been implicated in the production of the 
symptoms of MS(Moreau et al., 1996). INF directly or indirectly inhibits both the 
production of a number of those associated inflammatory factors (including interferon 
gamma) and the ability of those factors to stimulate nitric oxide release from 
astrocytes(Stewart et al., 1997). Elevated nitric oxide production and the consequent damage 
to mitochondria in surrounding neurons may be mitigated by INF and this could be a 
mechanism of action of INF in patients with MS(Stewart, Land, Clark, & Heales, 1998). 
NAA is produced by neuronal mitochondria(Patel & Clark, 1979), this could explain the 
recovery of NAA in patients with MS who are treated with INF. The increase in NAA 
could also be associated with the reversal of axonal metabolic dysfunction that is associated 
with in apparent myelin pathology in the NAWM.  
In this study, one of the principal effects, which seems to be due to INF-1a, was an increase 
in the total Cho peak, which in the NAWM became evident during the sixth month of 
treatment and persisted through the twelfth month, and in the WML became evident during 
the first month of treatment then persisted throughout the study period. Choline-containing 
compounds are considered to be turnover products of cell membranes, and an increase in 
the level of Cho seems to be related primarily to inflammatory and glial cell proliferation 
rather than to myelin destruction. This observation was confirmed in a histopathological 
and spectroscopic correlative study in EAE, the results of which showed that a high Cho 
was associated with inflammation and not with demyelination. Furthermore, glial 
proliferation in bioptic samples from patients with MS was consistent with an in vivo 
increase in Cho(Brenner et al., 1993). An increased level of Cho has been described in MS 
lesions in a variety of studies(Bitsch et al., 1999; Davie et al., 1994; Kapeller et al., 2001; 
Narayana et al., 1998). Myelin and membrane constituents make a major contribution to the 
constituent of Cho; therefore, increased lesion cellularity and turn over may account for the 
observed increase in the level of Cho. However, an increase in Cho has been interpreted as 
an index of active or recent demyelination by some authors(Confort-Gouny et al., 1993; 
Davie et al., 1994; Kapeller et al., 2001; Larsson et al., 1991), an association suggested by the 
finding of an abundance of Cho-containing compounds in myelin and in all cell membranes, 
including those of inflammatory cells, in patients with MS(Brenner et al., 1993). This increase 
in the level of Cho may occur without significant clinical deterioration or disease activity. In 
a recent study, an increase in metabolite concentrations of Cho and Cr was found in CIS 
NAWM(Fernando et al., 2004). H-MRS-visible Cho containing compounds are derived 
primarily from cell membranes and may be elevated when there is increased cell turnover. 
Because the relation between the variations in Cho levels and the pathological changes in 
underlying lesions is not very well known at the moment, it cannot be excluded that the rise 
in Cho peak could express an increased turnover of myelin in the plaques and NAWM 
examined, a turnover that may not be the result of new demyelination, but the consequence 
of the remodeling of plaques or the effects of a remyelination process.  
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Although an increase in the Cr level has been found in the NAWM of patients with MS(Brex 
et al., 1999; Rooney et al., 1997; Suhy et al., 2000; van Walderveen, Barkhof et al., 1999), some 
experts do not agree on the fluctuations of that metabolite in MS lesions. However, some 
authors have reported a decrease in total Cr(van Walderveen, Barkhof et al., 1999); others 
have reported an increase(Kapeller et al., 2001; Suhy et al., 2000). It has been suggested that 
apart from the axonal damage occurring in the NAWM of patients with MS, there is a 
proliferation of glial cells that produces an increase in the Cr level(Pan et al., 1996; van 
Walderveen, Barkhof et al., 1999). When working at 4.1tesla with 0.5 voxels, Pan and 
colleagues found an isolated increase in the Cr level without concomitant changes in Cho or 
NAA levels in the WM far from the WM lesions and suggested that in NAWM, there may 
have been reactive astrocytosis without inflammatory changes. It has been postulated that 
an increase in the Cr level may reflect an astrocytic (gliotic) or oligodendrocytic 
remyelinating process. Histological evidence confirms that gliosis is the most common 
abnormality in macroscopically normal WM of patients with MS. Thus the MRSI 
abnormalities observed in such patients may be due to the effect of microscopic lesions 
below the resolution of the images(Rooney et al., 1997; Suhy et al., 2000). However, the 
increase in Cr along with Cho levels in NAWM and WM may also be accounted for an 
increase in metabolism, which might be expected to occur with inflammatory or glial 
reactive features like those in the NAWM of patients with MS. 
There are some limitations of our study: The small number of patients, the short duration of 
study, an open label design, and the patients’ being either in relatively early stages of 
disease or experiencing a relatively benign course of MS. However the numbers of patients 
in relatively early stages of the disease are more or less similar between the groups, and 
again the ones with a relatively benign form are again similarly distributed between the 
groups. Therefore we do not consider that this would have caused a bias in our results. It 
would have been better if the study were performed with a greater number of patients along 
with a longer study period. However we could not perform such a more desirable study 
design because of ethical problems.       
5. Conclusions 
Our results showed that NAA, Cho and Cr in a VOI that predominantly contains NAWM 
increased in patients with MS after 1 year of treatment with INF-1a. The same effect was 
also observed in WML after treatment. This evidence supports the theory that although 
axonal pathology begins early in the course of MS, INF-1a therapy may reverse part of that 
early axonal and metabolic dysfunction, and thus inhibit permanent axonal loss. Follow-up 
studies could help to define the dynamic changes of metabolites in MS plaques and to 
monitor the disease progression in MS.  
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